



Galapagos NV

Issuance of warrants with cancellation of the preferential subscription right

Statutory auditor's report to the board of directors of Galapagos NV in accordance with articles 596 and 598 of the Companies Code

The original text of this report is in Dutch

Issuance of warrants with cancellation of the preferential subscription right Statutory auditor's report to the board of directors of Galapagos NV in accordance with articles 596 and 598 of the Companies Code

In accordance with articles 596 and 598 of the Companies Code, we have reviewed the attached special report of the board of directors of 19 September 2019. This report relates to the cancellation of the preferential subscription rights of the existing shareholders in favor of Gilead Therapeutics A1 Unlimited Company in the framework of the proposed issuance of warrants.

The purpose of this report is – according to said articles – the following:

Article 596:

"The general shareholders' meeting, which has to discuss and conclude on the capital increase, the issuance of convertible bonds or the issuance of warrants, can, taking into account the requirements with respect to quorum and majority required for an amendment to the articles of association, in the interest of the company, limit or cancel the preferential subscription right. The proposal thereto has to be specifically mentioned in the invitation.

The board of directors justifies its proposal in a detailed report that specifically relates to the issuance price and to the financial consequences of the transaction for the shareholders. A report has to be drafted by the statutory auditor or, in his absence, by a certified auditor assigned by the board of directors, or by an external accountant, assigned in the same way, in which he states that the financial and accounting information, included in the report of the board or directors, is accurate and sufficient to inform the general shareholders' meeting that has to vote on this proposal. The reports are deposited at the Court Registry of Commerce, in accordance with article 75. They are mentioned in the agenda. A copy can be obtained in accordance with article 535.

The absence of the reports mentioned in this article has the annulment of the decision of the general shareholders' meeting as a consequence.

The decision of the general shareholders' meeting to limit or cancel the preferential subscription right has to be deposited at the Court Registry of Commerce, in accordance with article 75."

Article 598:

"In case the preferential subscription right is limited or cancelled in the interest of one or more individuals who are not employees of the company or of one of its subsidiaries, the identity of the beneficiary or beneficiaries of the limitation or cancellation of the preferential subscription right must be mentioned in the report of the board of directors as well as in the invitation.

In addition, for companies, quoted on a stock exchange, the issuance price cannot be below the average stock price, from the thirty days prior to the day on which the issuance started.

For the other companies than those mentioned in the second paragraph, the issuance price has to be at least equal to the determined intrinsic value of the effect, which is, except when there is unanimous agreement between the shareholders, determined on the basis of a report from either the statutory auditor, either – for the companies which have no statutory auditor – by a certified auditor assigned by the board of directors, or by an external accountant, assigned in the same way.

The reports, drafted by the board of directors, have to mention the consequence of the proposed issuance on the former shareholder's situation, especially relating to his share in the earnings and the share capital. A statutory auditor, or in his absence, a certified auditor, assigned by the board of directors, or an external accountant assigned in the same way, has to prepare a detailed advise on the elements based upon which the issuance price has been calculated, as well as on its justification."

In our opinion, and in accordance with the attached special report concerning articles 583, 596 and 598 of the Belgian Companies Code, the financial and accounting information in the attached special report of the board of directors as of 19 September 2019 is accurate and sufficient to inform the shareholders on the proposed cancellation of the preferential subscription right of the existing shareholders in favour of Gilead Therapeutics A1 Unlimited Company within the framework of the proposed issuance of warrants.


The exercise price for Initial Warrant A (as defined in the board report) within the framework of this transaction is equal to 140,59 EUR per share and for the Initial Warrant B (as defined in the board report) it is equal to the greater of 120% multiplied by the arithmetic mean of the daily volume weighted average trading price of the shares of Galapagos NV (the "Company") as traded on Euronext (Brussels and Amsterdam) (or such other regulated markets on which the Company's shares will be trading at that time) on each of the trading days during the period of 30 calendar days ending on the calendar day immediately preceding the date of the Exercise Notice (as defined in the terms and conditions of the warrants attached to the board report) with respect to such exercise, and 140,59 EUR.

The exercise price of 140,59 EUR of Initial Warrant A and the floor exercise price of Initial Warrant B represent a 20% premium as compared to the average of the volume weighted average prices of the Company's shares on the regulated market of Euronext (Brussels and Amsterdam) during the thirty calendar days preceding the date of signing the Subscription Agreement (as defined in the board report) agreed between the Company and Gilead Therapeutics A1 Unlimited Company and are in accordance with article 598 of the Belgian Company Code which is stipulating that the exercise price cannot be below the average stock price, from the thirty days prior to the day on which the issuance started in case the preferential subscription right is limited or cancelled in the interest of one or more individuals who are not employees of the Company or of one of its subsidiaries.

This report is intended solely for the use of the shareholders of the Company in the framework of the cancellation of the preferential subscription right as described above. It therefore cannot be used for any other purpose.

Zaventem, 19 September 2019

The statutory auditor



Deloitte Bedrijfsrevisoren/Réviseurs d'Entreprises CVBA/SCRL
Represented by Gert Vanhees

Appendix: Special report of the board of directors of 19 September 2019 in accordance with article 583, 596 and 598 of the Belgian Companies Code relating to the cancellation of the preferential subscription rights of the existing shareholders in favor of Gilead Therapeutics A1 Unlimited Company within the framework of the proposed issuance of warrants.

Deloitte.

Deloitte Bedrijfsrevisoren/Réviseurs d'Entreprises
Coöperatieve vennootschap met beperkte aansprakelijkheid/Société coopérative à responsabilité limitée
Registered Office: Gateway building, Luchthaven Brussel Nationaal 1 J, B-1930 Zaventem
VAT BE 0429.053.863 - RPR Brussel/RPM Bruxelles - IBAN BE 17 2300 0465 6121 - BIC GEBABEBB

Member of Deloitte Touche Tohmatsu Limited